索拉非尼治疗伴有 C-KIT 外显子 11 缺失突变的复发性胸腺癌的疗效确切。
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
机构信息
Baskent University, School of Medicine, Dept. of Medical Oncology, Adana, Turkey.
出版信息
Lung Cancer. 2011 Jan;71(1):109-12. doi: 10.1016/j.lungcan.2010.09.011.
Abstract
Advanced thymic carcinoma (TC) is a very aggressive disease. To date there are no established treatment options for the refractory and recurrent disease and only a few prospective trials have been conducted in patients with TC. Here we present a case of a relapsed TC patient, who, by using combination chemotherapy, showed a positive response to sorafenib with C-KIT exon 11 mutation.
摘要
晚期胸腺癌（TC）是一种侵袭性很强的疾病。迄今为止，对于难治性和复发性疾病尚无既定的治疗选择，仅对少数 TC 患者进行了一些前瞻性试验。在此，我们报告了一例复发性 TC 患者的病例，该患者使用联合化疗，对伴有 C-KIT 外显子 11 突变的索拉非尼表现出积极的反应。
Zotero 插件